real-time news and commentary for investors
Friday, Feb 15
Amicus Therapeutics (FOLD -24.7%) tanks after reporting additional Stage 1 results from the...
Amicus Therapeutics (FOLD -24.7%) tanks after reporting additional Stage 1 results from the ongoing Phase 3 study of oral migalastat HCl monotherapy in patients with Fabry disease. Initial top-line results previously reported in December, 2012 for the primary endpoint in Stage 1 did not meet statistical significance. The pre-specified primary and secondary analyses of the primary endpoint numerically favored migalastat HCl over placebo, but not enough to allay investor concerns.